These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26280815)

  • 1. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
    Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
    Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
    Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
    Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
    Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
    Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer: Urinary PCA3 and TMPRSS2:ERG reduce the need for repeat biopsy.
    Sidaway P
    Nat Rev Urol; 2015 Oct; 12(10):536. PubMed ID: 26345208
    [No Abstract]   [Full Text] [Related]  

  • 12. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
    JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
    Feibus AH; Sartor O; Moparty K; Chagin K; Kattan MW; Ledet E; Levy J; Lee B; Thomas R; Silberstein JL
    J Urol; 2016 Oct; 196(4):1053-60. PubMed ID: 27140073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS;
    Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
    Young A; Palanisamy N; Siddiqui J; Wood DP; Wei JT; Chinnaiyan AM; Kunju LP; Tomlins SA
    Am J Clin Pathol; 2012 Nov; 138(5):685-96. PubMed ID: 23086769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
    Pepe P; Aragona F
    Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.
    Tallon L; Luangphakdy D; Ruffion A; Colombel M; Devonec M; Champetier D; Paparel P; Decaussin-Petrucci M; Perrin P; Vlaeminck-Guillem V
    Int J Mol Sci; 2014 Jul; 15(8):13299-316. PubMed ID: 25079439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.